Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

The common side effects of all PARP inhibitors include: nausea, vomiting, fatigue, upset stomach and bone marrow issues. Each of three types of PARP inhibitors–Niraparib, Rucaparib, and Olaparib–have ...

Type 1 diabetes occurs when the immune system attacks pancreatic beta cells. Type 2 diabetes happens when the body cannot use insulin effectively. The two types differ in symptoms, causes ...

This complex multifactorial disease has chronic and progressive pathology characterized by lipid accumulation, low-grade inflammation in the walls of large- and medium-sized arteries, and endothelial ...

Diabetes. 2005;54(12):3435-3441.

Eikon’s EIK1003 selectively inhibits PARP1 with the goal of offering the same efficacy as currently available PARP inhibitors while avoiding the toxicity of those drugs. EIK1003 is in Phase 1 ...

Body Dimensions 145 x 70.4 x 8.6 mm (5.71 x 2.77 x 0.34 in) ...

Several PPAR-targeting molecules, including dual agonists ... Detailed experimental protocols are provided in online supplementary file 1. Plasma FGF21 and insulin, respectively, were assayed using ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

Molecular mechanism studies demonstrated that FMN had this effect because it could target the activation of the Nrf2 pathway, increase the activity of the phase II metabolizing enzyme glutathione ...